Scarica l'app Stockscreener
1.01
3.81%
0.0371
Precedente Chiudi:
$0.9729
Aprire:
$0.9677
Volume 24 ore:
1.66M
Relative Volume:
1.01
Capitalizzazione di mercato:
$116.48M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.6121
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
-2.88%
1M Prestazione:
-6.48%
6M Prestazione:
+11.59%
1 anno Prestazione:
-71.55%
Intervallo 1D:
$0.9603
$1.01
Intervallo di 1 settimana:
$0.95
$1.0791
Portata 52W:
$0.6611
$4.20
Fate Therapeutics Inc Stock (FATE) Company Profile
Nome
Fate Therapeutics Inc
Settore
Industria
Telefono
858.875.1803
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Confronta FATE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.01 | 112.20M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-01-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Downgrade | Stifel | Buy → Hold |
| 2023-01-06 | Downgrade | Truist | Buy → Hold |
| 2023-01-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-12-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-11-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2022-07-28 | Iniziato | Needham | Hold |
| 2022-07-11 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-11 | Ripresa | BMO Capital Markets | Market Perform |
| 2021-12-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Jefferies | Buy |
| 2021-02-26 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-27 | Ripresa | H.C. Wainwright | Neutral |
| 2020-05-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-09 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Reiterato | Mizuho | Buy |
| 2019-12-09 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-06-07 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2019-03-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-03 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Iniziato | Jefferies | Buy |
| 2018-08-01 | Iniziato | Citigroup | Buy |
| 2018-03-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mostra tutto
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Price Floor Holding on Fate Therapeutics Inc. — Rebound PossibleJuly 2025 Summary & Verified Short-Term Trading Plans - beatles.ru
Using data models to predict Fate Therapeutics Inc. stock movementEarnings Recap Summary & Consistent Return Investment Signals - Newser
Volume spikes in Fate Therapeutics Inc. stock – what they meanGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Heatmap analysis for Fate Therapeutics Inc. and competitorsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - Newser
Visual trend scoring systems applied to Fate Therapeutics Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Fate Therapeutics Inc.July 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Layoff Tracker: AC Immune To Cut 30% of Workforce - biospace.com
Can technical indicators confirm Fate Therapeutics Inc.’s reversalSwing Trade & Stock Market Timing Techniques - Newser
What are analysts’ price targets for Fate Therapeutics Inc.2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک
Key metrics from Fate Therapeutics Inc.’s quarterly dataEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser
Does Fate Therapeutics Inc. show high probability of rebound2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Detecting support and resistance levels for Fate Therapeutics Inc.Weekly Stock Recap & Target Return Focused Picks - Newser
Can volume confirm reversal in Fate Therapeutics Inc.2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Institutional scanner results for Fate Therapeutics Inc.Trade Volume Summary & Growth Focused Entry Point Reports - Newser
Will Fate Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Weekly High Conviction Trade Ideas - Newser
Is Fate Therapeutics Inc. trending in predictive chart modelsWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Can machine learning forecast Fate Therapeutics Inc. recoveryPrice Action & Stock Market Timing Techniques - Newser
Fate Therapeutics' Equity Incentive Strategy and Its Implications for Talent Retention and Long-Term Value Creation - AInvest
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics shares rise 3% after-hours following new employee inducement grants. - AInvest
Is Fate Therapeutics Inc. stock entering bullish territoryTrade Exit Summary & Weekly High Potential Alerts - Newser
Leerink Partners lowers Fate Therapeutics stock price target to $7 on iPSC CAR’iT pivot - Investing.com Canada
Does Fate Therapeutics Inc. align with a passive investing strategyInflation Watch & Consistent Income Trade Recommendations - خودرو بانک
What are Fate Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Review & Breakout Confirmation Trade Signals - خودرو بانک
Why Fate Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Short-Term Trading Alerts - Newser
Published on: 2025-09-03 09:36:15 - Newser
Has Fate Therapeutics Inc. found a price floorWall Street Watch & Risk Managed Trade Strategies - Newser
Will Fate Therapeutics Inc. stock hit new highs in YEARGap Down & Verified Swing Trading Watchlist - خودرو بانک
Chart overlay techniques for tracking Fate Therapeutics Inc.2025 Technical Patterns & Entry and Exit Point Strategies - Newser
Building trade automation scripts for Fate Therapeutics Inc.M&A Rumor & Low Risk Entry Point Tips - Newser
Is Abeona Therapeutics Inc. attractive at current valuationTrade Performance Summary & Community Trade Idea Sharing - خودرو بانک
Backtesting results for Fate Therapeutics Inc. trading strategiesMarket Trend Review & Smart Allocation Stock Reports - Newser
Market reaction to Fate Therapeutics Inc.’s recent newsJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
What is Fate Therapeutics Inc. s 5 year growth outlookTrade Volume Report & Weekly Breakout Stock Alerts - خودرو بانک
Is Fate Therapeutics Inc. forming a bottoming baseJuly 2025 Sector Moves & Stock Portfolio Risk Management - Newser
Fate Therapeutics Inc. Crosses 200 Day MA — Signal or Noise getLinesFromResByArray error: size == 0 - 강소기업뉴스
Will Fate Therapeutics Inc. stock go up soon2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Comparing Fate Therapeutics Inc. in custom built stock radarsRisk Management & Weekly Top Performers Watchlists - Newser
What is Fate Therapeutics Inc.’s valuation compared to sectorMarket Activity Report & Fast Entry Momentum Alerts - خودرو بانک
Published on: 2025-09-01 01:36:52 - Newser
Fate Therapeutics Inc. stock trend forecastEarnings Summary Report & Community Driven Trade Alerts - Newser
Understanding Fate Therapeutics Inc.’s price movementMarket Movement Recap & Real-Time Buy Zone Alerts - Newser
How to interpret RSI for Fate Therapeutics Inc. stockLong Setup & Advanced Technical Analysis Signals - Newser
Fate Therapeutics Inc Azioni (FATE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):